Krystal Biotech, Inc. KRYS Business Segments — Operating Income (Loss)

Similar metrics at other companies

BBIOReportable Segment — Operating Income (Loss)

-$105.96M-1.5%

BBIOReportable Segment Aggregation Before Other Operating — Operating Income

-$134.28M+23.5%

VRSKOperating Segments — Operating Income

$198.42M+0.6%

POWLReportable Segment — Operating Income (Loss)

$42.77M+20.2%

IOTReportable Segment — Operating Income (Loss)

$7.2M+122%

WSMReportable Segment — Operating Income (Loss)

$291.69M+0.3%

Questions, answered.

What is Krystal Biotech, Inc.'s business segments — operating income (loss)?

Krystal Biotech, Inc. (KRYS) reported business segments — operating income (loss) of $53.69M in Q1 2026.

How has Krystal Biotech, Inc.'s business segments — operating income (loss) changed year-over-year?

Krystal Biotech, Inc.'s business segments — operating income (loss) increased by 48.1% year-over-year, from $36.25M to $53.69M.

What is the long-term trend for Krystal Biotech, Inc.'s business segments — operating income (loss)?

Over 3 years (2022 to 2025), Krystal Biotech, Inc.'s business segments — operating income (loss) has grown at a 3.5% compound annual growth rate (CAGR), from -$145.2M to $161.2M.

What does business segments — operating income (loss) mean?

The profit or loss from core business operations before interest and taxes.

How do you interpret business segments — operating income (loss)?

Positive and growing operating income signals a self-sustaining business model, whereas losses indicate continued reliance on capital or early-stage status.

How does business segments — operating income (loss) compare across companies?

Operating profitability is a key milestone for biotech companies moving from R&D-focused entities to commercial-stage enterprises.